Published in Obstet Gynecol on March 01, 2012
Viral DNA load of high-risk human papilloma virus is closely associated with the grade of cervical lesions. Int J Clin Exp Med (2014) 0.75
The Women's Interagency HIV Study. WIHS Collaborative Study Group. Epidemiology (1998) 12.32
Calculation of survival rates for cancer. Proc Staff Meet Mayo Clin (1950) 7.94
The Women's Interagency HIV Study: an observational cohort brings clinical sciences to the bench. Clin Diagn Lab Immunol (2005) 7.30
ACOG Practice Bulletin no. 109: Cervical cytology screening. Obstet Gynecol (2009) 4.27
Cervicovaginal human papillomavirus infection in human immunodeficiency virus-1 (HIV)-positive and high-risk HIV-negative women. J Natl Cancer Inst (1999) 4.27
A systematic review of the prevalence and attribution of human papillomavirus types among cervical, vaginal, and vulvar precancers and cancers in the United States. Cancer Epidemiol Biomarkers Prev (2008) 2.10
Marginal and mixed-effects models in the analysis of human papillomavirus natural history data. Cancer Epidemiol Biomarkers Prev (2010) 2.00
Squamous cervical lesions in women with human immunodeficiency virus: long-term follow-up. Obstet Gynecol (2008) 1.47
Retention and attendance of women enrolled in a large prospective study of HIV-1 in the United States. J Womens Health (Larchmt) (2009) 1.33
Outcome of treated anogenital intraepithelial neoplasia among human immunodeficiency virus-infected women. J Reprod Med (2008) 0.87
Hysterectomy among women with HIV: indications and incidence. J Acquir Immune Defic Syndr (2007) 0.82
Cervicovaginal human papillomavirus (HPV)-infection before and after hysterectomy: evidence of different tissue tropism for oncogenic and nononcogenic HPV types in a cohort of HIV-positive and HIV-negative women. Int J Cancer (2012) 0.82
Distinct risk factor profiles for human papillomavirus type 16-positive and human papillomavirus type 16-negative head and neck cancers. J Natl Cancer Inst (2008) 8.70
HPV-associated head and neck cancer: a virus-related cancer epidemic. Lancet Oncol (2010) 6.53
A piece of my mind. Winners and losers. JAMA (2004) 5.59
Natural history and possible reactivation of human papillomavirus in human immunodeficiency virus-positive women. J Natl Cancer Inst (2005) 5.29
Risk of HIV-1 acquisition among women who use diff erent types of injectable progestin contraception in South Africa: a prospective cohort study. Lancet HIV (2015) 4.33
Diabetes, metformin, and breast cancer in postmenopausal women. J Clin Oncol (2012) 3.47
The prognostic importance of changes in CD4+ cell count and HIV-1 RNA level in women after initiating highly active antiretroviral therapy. Ann Intern Med (2004) 3.05
Human papillomavirus type 16 and immune status in human immunodeficiency virus-seropositive women. J Natl Cancer Inst (2003) 2.81
Invasive cervical cancer risk among HIV-infected women: a North American multicohort collaboration prospective study. J Acquir Immune Defic Syndr (2013) 2.78
Vitamin D deficiency in HIV-infected and HIV-uninfected women in the United States. J Acquir Immune Defic Syndr (2011) 2.65
Head and neck squamous cell cancer and the human papillomavirus: summary of a National Cancer Institute State of the Science Meeting, November 9-10, 2008, Washington, D.C. Head Neck (2009) 2.59
Risk of anal cancer in HIV-infected and HIV-uninfected individuals in North America. Clin Infect Dis (2012) 2.50
Patterns of the hazard of death after AIDS through the evolution of antiretroviral therapy: 1984-2004. AIDS (2005) 2.42
Highly active antiretroviral therapy and cervical squamous intraepithelial lesions in human immunodeficiency virus-positive women. J Natl Cancer Inst (2004) 2.23
Association of cigarette smoking with HIV prognosis among women in the HAART era: a report from the women's interagency HIV study. Am J Public Health (2006) 2.19
Safety of tenofovir use during pregnancy: early growth outcomes in HIV-exposed uninfected infants. AIDS (2012) 2.19
Sex differences in pharmacokinetics and pharmacodynamics. Annu Rev Pharmacol Toxicol (2004) 2.17
Cervical shedding of HIV-1 RNA among women with low levels of viremia while receiving highly active antiretroviral therapy. J Acquir Immune Defic Syndr (2007) 2.11
Causes of death among women with human immunodeficiency virus infection in the era of combination antiretroviral therapy. Am J Med (2002) 2.11
Effects of bacterial vaginosis and other genital infections on the natural history of human papillomavirus infection in HIV-1-infected and high-risk HIV-1-uninfected women. J Infect Dis (2005) 2.04
Eligibility criteria for HIV clinical trials and generalizability of results: the gap between published reports and study protocols. AIDS (2005) 2.03
Marginal and mixed-effects models in the analysis of human papillomavirus natural history data. Cancer Epidemiol Biomarkers Prev (2010) 2.00
Interobserver agreement in the assessment of components of colposcopic grading. Obstet Gynecol (2008) 1.96
The association of race, sociodemographic, and behavioral characteristics with response to highly active antiretroviral therapy in women. J Acquir Immune Defic Syndr (2005) 1.96
The effect of HIV infection and HAART on inflammatory biomarkers in a population-based cohort of women. AIDS (2011) 1.94
Pregnancy rates and predictors of conception, miscarriage and abortion in US women with HIV. AIDS (2004) 1.94
Risk factors for acquisition and clearance of oral human papillomavirus infection among HIV-infected and HIV-uninfected adults. Am J Epidemiol (2014) 1.88
Incidence of cervical squamous intraepithelial lesions associated with HIV serostatus, CD4 cell counts, and human papillomavirus test results. JAMA (2005) 1.86
Cumulative Incidence of Cancer Among Persons With HIV in North America: A Cohort Study. Ann Intern Med (2015) 1.86
Influence of adherent and effective antiretroviral therapy use on human papillomavirus infection and squamous intraepithelial lesions in human immunodeficiency virus-positive women. J Infect Dis (2010) 1.85
Improved obstetric outcomes and few maternal toxicities are associated with antiretroviral therapy, including highly active antiretroviral therapy during pregnancy. J Acquir Immune Defic Syndr (2005) 1.84
Factors associated with use of dental services among HIV-infected and high-risk uninfected women. J Am Dent Assoc (2005) 1.79
Protease inhibitor use and the incidence of diabetes mellitus in a large cohort of HIV-infected women. J Acquir Immune Defic Syndr (2003) 1.78
Risk of progression to AIDS and death in women infected with HIV-1 initiating highly active antiretroviral treatment at different stages of disease. Arch Intern Med (2002) 1.75
Does patient sex affect human immunodeficiency virus levels? Clin Infect Dis (2002) 1.72
HIV-1 in genital tract and plasma of women: compartmentalization of viral sequences, coreceptor usage, and glycosylation. Proc Natl Acad Sci U S A (2003) 1.71
Atazanavir concentration in hair is the strongest predictor of outcomes on antiretroviral therapy. Clin Infect Dis (2011) 1.70
Risk factors for oral HPV infection among a high prevalence population of HIV-positive and at-risk HIV-negative adults. Cancer Epidemiol Biomarkers Prev (2011) 1.68
Protease inhibitor levels in hair strongly predict virologic response to treatment. AIDS (2009) 1.68
Pharmacokinetics and safety of stavudine in HIV-infected pregnant women and their infants: Pediatric AIDS Clinical Trials Group protocol 332. J Infect Dis (2004) 1.67
Total lymphocyte count, hemoglobin, and delayed-type hypersensitivity as predictors of death and AIDS illness in HIV-1-infected women receiving highly active antiretroviral therapy. J Acquir Immune Defic Syndr (2004) 1.66
Three postpartum antiretroviral regimens to prevent intrapartum HIV infection. N Engl J Med (2012) 1.63
Maternal toxicity with continuous nevirapine in pregnancy: results from PACTG 1022. J Acquir Immune Defic Syndr (2004) 1.60
Bacterial vaginosis: identifying research gaps proceedings of a workshop sponsored by DHHS/NIH/NIAID. Sex Transm Dis (2010) 1.59
Changes in sexual behavior among HIV-infected women after initiation of HAART. Am J Public Health (2004) 1.59
Prevalence and predictors of Toxoplasma seropositivity in women with and at risk for human immunodeficiency virus infection. Clin Infect Dis (2002) 1.59
Impact of highly active antiretroviral therapy on anemia and relationship between anemia and survival in a large cohort of HIV-infected women: Women's Interagency HIV Study. J Acquir Immune Defic Syndr (2004) 1.58
Serum immunoglobulin G response to human papillomavirus type 16 virus-like particles in human immunodeficiency virus (HIV)-positive and risk-matched HIV-negative women. J Infect Dis (2003) 1.57
Timing of repeat colonoscopy: disparity between guidelines and endoscopists' recommendation. Am J Prev Med (2007) 1.53
The association of serum ferritin and transferrin receptor concentrations with mortality in women with human immunodeficiency virus infection. Haematologica (2006) 1.53
Reproductive health of adolescent girls perinatally infected with HIV. Am J Public Health (2007) 1.53
Functional attributes of mucosal immunity in cervical intraepithelial neoplasia and effects of HIV infection. Cancer Res (2004) 1.50
Antiretrovirals in pregnancy: a note of caution. J Infect Dis (2012) 1.49
Two-week versus six-month sampling interval in a short-term natural history study of oral HPV infection in an HIV-positive cohort. PLoS One (2010) 1.49
Live birth patterns among human immunodeficiency virus-infected women before and after the availability of highly active antiretroviral therapy. Am J Obstet Gynecol (2007) 1.48
Squamous cervical lesions in women with human immunodeficiency virus: long-term follow-up. Obstet Gynecol (2008) 1.47
Relationship between prevalent oral and cervical human papillomavirus infections in human immunodeficiency virus-positive and -negative women. J Clin Microbiol (2006) 1.46
Methicillin-resistant Staphylococcus aureus necrotizing pneumonia arising from an infected episiotomy site. Obstet Gynecol (2007) 1.46
Higher tenofovir exposure is associated with longitudinal declines in kidney function in women living with HIV. AIDS (2016) 1.45
Characteristics of Early Recipients of Patient-Centered Outcomes Research Institute Funding. Acad Med (2016) 1.44
Sensitive analysis of anti-HIV drugs, efavirenz, lopinavir and ritonavir, in human hair by liquid chromatography coupled with tandem mass spectrometry. Rapid Commun Mass Spectrom (2008) 1.44
Long-term incidence of cervical cancer in women with human immunodeficiency virus. Cancer (2009) 1.42
Challenging the strategy of maternal age-based prenatal genetic counseling. JAMA (2006) 1.41
Factors associated with preclinical disability and frailty among HIV-infected and HIV-uninfected women in the era of cART. J Womens Health (Larchmt) (2009) 1.41
Mouthwash use and cancer of the head and neck: a pooled analysis from the International Head and Neck Cancer Epidemiology Consortium. Eur J Cancer Prev (2016) 1.38
Natural history of anal vs oral HPV infection in HIV-infected men and women. J Infect Dis (2013) 1.37
Outcomes after treatment of cervical intraepithelial neoplasia among women with HIV. J Low Genit Tract Dis (2007) 1.37
Pharmacokinetics of saquinavir plus low-dose ritonavir in human immunodeficiency virus-infected pregnant women. Antimicrob Agents Chemother (2004) 1.35
Prevalence and correlates of highly active antiretroviral therapy switching in the Women's Interagency HIV Study. J Acquir Immune Defic Syndr (2002) 1.35
C-reactive protein is an independent predictor of mortality in women with HIV-1 infection. J Acquir Immune Defic Syndr (2003) 1.35
Retention and attendance of women enrolled in a large prospective study of HIV-1 in the United States. J Womens Health (Larchmt) (2009) 1.33
Pharmacokinetics and safety of indinavir in human immunodeficiency virus-infected pregnant women. Antimicrob Agents Chemother (2006) 1.32
The relationship between non-injection drug use behaviors on progression to AIDS and death in a cohort of HIV seropositive women in the era of highly active antiretroviral therapy use. Addiction (2005) 1.32
Factors and temporal trends associated with highly active antiretroviral therapy discontinuation in the Women's Interagency HIV Study. J Acquir Immune Defic Syndr (2005) 1.31